| Frank de Groot 2004-10-19, 7:14 pm |
| Date: Sat, 16 Oct 2004 22:17:44 +0100 (BST)
From: cristina gennari <cristinageja@yahoo.co.uk>
Subject: candida and borrelia study
Hi,
I found this and thought it was interesting:
http://www.ncbi.nlm.nih.gov/entrez/...t_uids=15337633
Clinical effects of fluconazole in patients with neuroborreliosis.
Schardt FW.
Betriebsarztliche Untersuchungsstelle, Bayerische
Julius-Maximilians-Universitat, Wurzburg, Germany.
Fritz.Schardt@mail.uni-wuerzburg.de
Eleven patients with neuro-borreliosis had been treated with 200 mg
fluconazole daily for 25 days after an unsuccessful therapy with
antibiotics. At the end of treatment eight patients had no borreliosis
symptoms and remained free of relapse in a follow-up examination one year
later. In the remaining four patients, symptoms were considerably improved.
At the end of therapy immune reactivity (IgM+) disappeared in three
patients. Since borrelia spp. are almost exclusively localised
intracellular, they may depend on certain metabolites of their eucaryotic
host cell. Inhibition of P450 and other cytochromes by fluconazole may
incapacitate Borrelia upon longterm exposure.
|